Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744803 | 1.00 | MCHR1 (0.42) | MCHR1IRAK4HDAC1USP30ROCK2 | |
| SCHEMBL30345489 | 0.85 | MCHR1 (0.40) | MCHR1IRAK4HDAC1ROCK2ROCK1 | |
| SCHEMBL23744102 | 0.85 | MCHR1 (0.40) | MCHR1IRAK4HDAC1ROCK2ROCK1 | |
| SCHEMBL10219399 | 0.82 | HTR2C (0.42) | HRH3HTR2AHTR2CHTR2BPIM1 | |
| SCHEMBL23744103 | 0.81 | MCHR1 (0.42) | MCHR1HDAC1ROCK2ROCK1KDM4E | |
| SCHEMBL23744804 | 0.81 | SCN9A (0.42) | MCHR1USP30SCN9AHRH3MET | |
| SCHEMBL30345518 | 0.81 | SCN9A (0.42) | MCHR1USP30SCN9AHRH3MET | |
| SCHEMBL13666118 | 0.80 | HCAR2 (0.46) | HDAC1ROCK2ROCK1KDM4EPIM1 | |
| SCHEMBL1470530 | 0.79 | HDAC1 (0.47) | IRAK4HDAC1KDM4E | |
| SCHEMBL2178404 | 0.79 | HDAC1 (0.47) | IRAK4HDAC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | MCHR1 134/4885IRAK4 454/4885HDAC1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.